This is strongly supported by the ability of SIRT2-knockdown or SIRT2 inhibition, using salermide, to impede the metastasis of hepatocellular carcinoma, gastric cancer, and osteosarcoma cells in xenograft mouse models [63,64,65]. Here, SIRT2 is linked to hepatocellular carcinoma.